Arbutus Biopharma (ABUS) Times Interest Earned (2017 - 2026)
Arbutus Biopharma (ABUS) posted Times Interest Earned of $7343.8 for Q1 2026, up 2598.84% sequentially from -$293.89 in Q4 2025, and up 900.14% YoY from $734.28 in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Times Interest Earned (2017 - 2026) Analysis & Trends
Arbutus Biopharma has reported Times Interest Earned for 14 years, with the latest figure at $7343.8 in Q1 2026.
- Quarterly Times Interest Earned rose 900.14% year-over-year to $7343.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6802.0 (up 6263.85% YoY) and the FY2025 annual result came in at -$0.21, up 51.64% from the prior year.
- Times Interest Earned advanced to $7343.8 in Q1 2026 per ABUS's latest filing, from -$293.89 in the prior quarter.
- Over five years, Times Interest Earned peaked at $7343.8 in Q1 2026 and troughed at -$917.82 in Q1 2025.
- A 5-year average of $221.26 and a median of -$107.51 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2026: Times Interest Earned sank 1028.81% in 2023, then surged 900.14% in 2026.
- Over 5 years, Times Interest Earned stood at -$73.02 in 2022, then tumbled by 55.27% to -$113.37 in 2023, then soared by 75.86% to -$27.37 in 2024, then sank by 973.63% to -$293.89 in 2025, then surged by 2598.84% to $7343.8 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $7343.8, -$293.89, and -$376.48 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | -331.33 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -331.33 |
| Mar 31, 2026 | 9,935.76 |
| Dec 31, 2025 | -293.89 |
| Sep 30, 2025 | -376.48 |
| Jun 30, 2025 | 53.14 |
| Mar 31, 2025 | -917.82 |
| Dec 31, 2024 | -464.43 |
| Sep 30, 2024 | -739.31 |
| Jun 30, 2024 | -634.79 |
| Mar 31, 2024 | -440.07 |
| Dec 31, 2023 | -471.52 |
| Sep 30, 2023 | -468.65 |
| Jun 30, 2023 | -107.51 |
| Mar 31, 2023 | -87.94 |
| Dec 31, 2022 | -73.02 |
| Sep 30, 2022 | -41.52 |
| Jun 30, 2022 | -29.27 |
| Mar 31, 2022 | -21.69 |
| Dec 31, 2021 | -37.14 |
| Sep 30, 2021 | -24.16 |